Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05RRU
|
|||
| Former ID |
DIB012439
|
|||
| Drug Name |
IL-2/CD40L-expressing leukemia vaccine
|
|||
| Synonyms |
Autologous vaccine (leukemia), Baylor College of Medicine; Autologous vaccine (leukemia), MaxCyte; Autologous vaccine (leukemia), Baylor College of Medicine/MaxCyte; IL-2/CD40L-expressing leukemia vaccine, Baylor College of Medicine; IL-2/CD40L-expressing leukemia vaccine, MaxCyte; IL-2/CD40L-expressing leukemia vaccine, Baylor College of Medicine/MaxCyte
Click to Show/Hide
|
|||
| Drug Type |
Vaccine
|
|||
| Indication | Chronic lymphocytic leukaemia [ICD-11: 2A82.0; ICD-10: C83.0, C91.1] | Phase 2 | [1] | |
| Company |
Baylor College of Medicine
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01604031) Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide. U.S. National Institutes of Health. | |||
| REF 2 | Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and a... Blood. 2006 Feb 15;107(4):1332-41. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.